INMUNE BIO INC. Fair Value of Assets Acquired
INMUNE BIO INC. (INMB) reported Fair Value of Assets Acquired of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueOfAssetsAcquired · last filed 2026-03-30
- INMUNE BIO INC. fair value of assets acquired for the quarter ending 2025-09-30 was $0.00.
| Period end | Fair Value of Assets Acquired 3 month | Fair Value of Assets Acquired 6 month | Fair Value of Assets Acquired 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-K 6 month · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $0.00 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |